It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.
therapeutic areas
Your partner for complex drug discovery across therapeutic areas.
At Sygnature Discovery we combine therapeutic area expertise and translational insight to design successful drug discovery strategies, reduce risk, and accelerate compounds towards the clinic. Our experts across a range of therapeutic areas provide strategic insight to ensure programs are well-informed by disease biology, stay clinically focused, and deliver meaningful impact for patients.
Achieving success in drug discovery demands more than data, it calls for disease relevant insight and an understanding of translational biology.
Our therapeutic area experts combine hands-on experience with strategic insight and align disciplinary expertise around your unique biological and clinical challenges. Their guidance ensures every decision is scientifically sound, translationally focused, and will move you forward with confidence.
We have extensive expertise in oncology, inflammation & immunity and neuroscience, as well as metabolic, infectious, fibrotic and respiratory diseases, and more.
By combining specialised expertise across disciplines, drug discovery stage and therapeutic areas we consider the needs of your program from a truly integrated perspective. We work in close partnership with you to build tailored solutions.
Our Therapeutic Areas
Our therapeutic area expertise ensures each project benefits from disease-relevant insight and translational focus.
Oncology
We deliver first- and best-in class oncology candidates by combining scientific expertise with cutting-edge discovery platforms. From leukemia to breast and prostate cancers, our teams design studies around clinically relevant biomarkers and endpoints helping partners make confidence, data-driven decisions.
We turn complex immune mechanisms into actionable insights using human-relevant in vitro systems. These models assess immune modulation and cytokine release to identify meaningful biomarkers and advance novel therapies for autoimmune, inflammatory, and immunoncology indications. Integrated with DMPK, medicinal chemistry, and in vivo pharmacology, we help you de-risk early programs .
Designing CNS-active compounds requires navigating challenges such as permeability, selectivity, safety, and efficacy. With extensive experience in neurodegenerative and neuroinflammatory diseases such as Alzheimer’s, Parkinson’s, and neuropathic pain, our teams guide programs from concept to IND with precision and translational focus.
Our teams have a strong track record in metabolic disease, delivering validated candidates across obesity, diabetes, and cardiometabolic disorders. By combining early medicinal chemistry, mechanistic in vitro biology, and translational in vivo studies, we generate compounds with real clinical promise, ready for the next stage of development.
Drug discovery is evolving, and so are the challenges. As global health demands rise, the need for smarter, faster, and more connected science has never been greater. Yet too often, progress is slowed by disconnection between disciplines and data.
At Sygnature Discovery, our aim is to reshape how drug discovery is delivered. Through flexible services and integrated expertise, we enable innovation at every stage. With AI and automation embedded across our workflows, we help you move faster and make confident decisions, delivering results with confidence and integrity.
Whether we’re supporting you through the entire process or just a part of it, our goal isn’t simply to move you to the next stage, it’s to lay the foundations for a successfully marketed drug.
Why Choose Sygnature Discovery?
Partnering with Sygnature means gaining access to over 700 scientists from more than 50 countries. With no internal drug discovery programs, we’re dedicated to your success.
Operating across three co-located and integrated discovery hubs in the UK and North America, we offer a seamless path from concept to candidate. Since 2011, we’ve delivered over 60 novel preclinical and 35+ clinical candidates, with our scientists named on more than 200 patents.
Choosing Sygnature means choosing scientific excellence, strategic partnership, and a global team dedicated to turning discovery into real-world impact.
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine. This is where collaborations with expert CROs like Sygnature Discovery can accelerate a drug discovery project towards the clinic.
